# A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer

> **NCT01801904** · PHASE2 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT01801904
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01801904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01801904, "A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01801904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*